Castle Biosciences (CSTL) came into focus for investors after management raised full year 2026 revenue guidance to a range of US$385 million to US$395 million, citing higher TissueCypher test volumes and better pricing. The raised guidance arrived alongside a share price that has been climbing in recent months, with a 90 day share price return of 16.44% and a 30 day share price return of 4.90%. However, the year to date share price return is still down 10.51% and the 5 year total shareholder...
Castle Biosciences reported third quarter 2026 revenue of US$102.89 million compared with US$83.04 million a year earlier, with a quarterly net loss of US$4.1 million and loss per share of US$0.13. The business raised its 2026 revenue outlook to a range of US$385 million to US$395 million and is pointing to positive adjusted EBITDA, supported by strong TissueCypher test adoption. We will look at how Castle Biosciences' investment narrative evolves as raised 2026 revenue guidance reshapes...
Castle Biosciences Inc (CSTL) raised full-year 2026 revenue guidance to $385-$395 million on strong TissueCypher growth, even as DecisionDx SCC pressures and a Q3 net loss temper the outlook.
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present a company overview at the Stephens Annual Investment Conference on Wednesday, Nov. 18, 2026, at 12:30 p.m. Central time.
Detailed price information for Castle Biosciences Inc (CSTL-Q) from The Globe and Mail including charting and trades.
A decision modeling study found that TissueCypher-guided care could increase appropriate treatment decisions for Barrett’s esophagus patients, including earlier escalation for non-dysplastic patients who later progress to high-grade dysplasia or cancer. Key Investor TakeawaysCastle Biosciences (NASDAQ:CSTL) reported a TissueCypher study showing appropriate Barrett’s esophagus management increased from 59.
SciBase Holding AB ("SciBase") (STO: SCIB), a leader in AI-based devices for detection and prevention in dermatology, today announces that it has received an additional order for an acceleration of the current, ongoing clinical study and preparations for a second clinical study under the collaboration with Castle Biosciences. The order consists of both the portable Nevisense Go pen device and electrodes to a value of around $0.6 million or approximately MSEK 5.
Does Castle Biosciences, Inc. (CSTL) have what it takes to be a top stock pick for momentum investors? Let's find out.
Shares of Castle Biosciences (CSTL) have recently risen about 37%, following increasing agreement among Wall Street analysts on earnings estimate revisions that point to a more constructive view of the company’s earnings outlook. At around $34.11 per share, Castle Biosciences has seen strong recent momentum, with a 30 day share price return of about 39.6% and a 90 day share price return of about 54.3%. The 1 year total shareholder return of about 53.1% suggests that recent optimism around...
The consensus price target hints at a 31.5% upside potential for Castle Biosciences (CSTL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
This is the newest page. Registered accounts read further back.